News

PDS Biotechnology Corp (PDSB) – As PDS0101 Trials Continue, Preparations For Pivotal Studies Begin.

Health
0 min read

Wednesday, August 10, 2022

PDS Biotechnology Corp (PDSB)
As PDS0101 Trials Continue, Preparations For Pivotal Studies Begin.

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Quarterly Loss Was Less Than We Estimated.  PDS Biotech reported 2Q22 loss of $5.8 million or $(0.20) per share, beating our estimated loss of $8.8 million or $(0.34) per share. The differences were largely due to R&D expense of $3.7 million compared with our estimate of $5.3 million, as well as a $1.2 million tax benefit. The company ended the quarter with $53.0 million in cash.

As The Versatile-002 Trial Continues, Phase 3 Planning Begins.  The Phase 2 Versatile-002 trial, testing PDS0101 in combination with the checkpoint inhibitor Keytruda, received a positive opinion from its independent Data Safety Monitoring Board. The recommendation was to continue the trial to completion without any changes to the protocol.  In June, the combination of PDS0101 with Keytruda received Fast-Track designation from the FDA….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.